ACADIA Pharmaceuticals(US:ACAD) ZACKSยท2025-11-06 17:26Core Insights - Acadia Pharmaceuticals reported Q3 2025 earnings of 26 cents per share, exceeding the Zacks Consensus Estimate of 14 cents, and up from 20 cents in the same quarter last year [1][8] - Total revenues for the quarter reached $278.6 million, surpassing the Zacks Consensus Estimate of $274 million, with an 11% year-over-year increase driven by sales of Nuplazid and Daybue [3][4][8] Financial Performance - Acadia's net product revenues from Nuplazid increased by 12% year-over-year to $177.5 million, exceeding the Zacks Consensus Estimate of $173 million [7][8] - Daybue recorded net product sales of $101.1 million, also up 11% year-over-year, slightly above the Zacks Consensus Estimate of $101 million [9][8] - Research and development expenses rose by 31.8% year-over-year to $87.8 million, while selling, general and administrative expenses remained almost flat at $133.4 million [9][10] Updated Financial Outlook - Acadia revised its 2025 total revenue guidance to a range of $1.070-$1.095 billion, up from the previous range of $1.045-$1.095 billion [11] - Nuplazid sales are now expected to be between $685 million and $695 million, an increase from the prior guidance of $665 million to $690 million [11] - Daybue sales are projected to be between $385 million and $400 million, slightly adjusted from the previous range of $380 million to $405 million [11] Pipeline Developments - A regulatory filing for trofinetide to treat Rett syndrome is under review in the EU, with an expected approval in Q1 2026 [13] - The phase III COMPASS PWS study for ACP-101 did not meet its primary endpoint, leading the company to discontinue further investigation of this candidate [14][15]